How Analysts Feel About AxoGen, Inc. (AXGN) After Making All-Time High?

March 14, 2018 - By Migdalia James

The stock of AxoGen, Inc. (NASDAQ:AXGN) reached all time high today, Mar, 14 and still has $36.98 target or 3.00 % above today’s $35.90 share price. This indicates more upside for the $1.24 billion company. This technical setup was reported by If the $36.98 PT is reached, the company will be worth $37.14M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 2.13% or $0.75 during the last trading session, reaching $35.9. About 113,979 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since March 14, 2017 and is uptrending. It has outperformed by 164.79% the S&P500.

Analysts await AxoGen, Inc. (NASDAQ:AXGN) to report earnings on May, 3. They expect $-0.11 EPS, 0.00 % or $0.00 from last year’s $-0.11 per share. After $-0.07 actual EPS reported by AxoGen, Inc. for the previous quarter, Wall Street now forecasts 57.14 % negative EPS growth.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 8 analysts covering AxoGen (NASDAQ:AXGN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 21 analyst reports since August 11, 2015 according to SRatingsIntel. Lake Street downgraded it to “Hold” rating and $9 target in Thursday, November 3 report. Roth Capital maintained AxoGen, Inc. (NASDAQ:AXGN) rating on Monday, September 11. Roth Capital has “Buy” rating and $21.0 target. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Outperform” rating given on Monday, November 7 by Wedbush. As per Friday, March 2, the company rating was maintained by Lake Street. The company was maintained on Thursday, November 2 by Leerink Swann. Wedbush maintained AxoGen, Inc. (NASDAQ:AXGN) rating on Friday, August 28. Wedbush has “Outperform” rating and $5 target. The firm earned “Market Outperform” rating on Thursday, March 1 by JMP Securities. The stock has “Buy” rating by Cantor Fitzgerald on Monday, August 21. The rating was upgraded by Lake Street to “Buy” on Tuesday, November 22. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, November 21 report.

More notable recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: which released: “AxoGen, Inc. to Present at 30th Annual ROTH Conference” on February 20, 2018, also with their article: “AxoGen Named Employee Engagement Best Practices Award Winner by DecisionWise …” published on February 27, 2018, published: “AxoGen, Inc. to Report Fourth Quarter and Full-Year 2017 Financial Results and …” on February 14, 2018. More interesting news about AxoGen, Inc. (NASDAQ:AXGN) were released by: and their article: “AxoGen, Inc. to Present at Canaccord Genuity Musculoskeletal Conference” published on February 20, 2018 as well as‘s news article titled: “AxoGen, Inc. Reports 2017 Fourth Quarter and Full Year Financial Results” with publication date: February 28, 2018.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $1.24 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: